TOVX logoTOVX
Theriva Biologics Inc

23,346
Loading...
Loading...
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer on January 8, 2001 and is headquartered in Rockville, MD.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
22

Frequently Asked Questions

What is Market Cap of Theriva Biologics Inc?
What is the 52-week high for Theriva Biologics Inc?
What is the 52-week low for Theriva Biologics Inc?
What is Theriva Biologics Inc stock price today?
What was Theriva Biologics Inc stock price yesterday?
What is the PE ratio of Theriva Biologics Inc?
What is the Price-to-Book ratio of Theriva Biologics Inc?
What is the 50-day moving average of Theriva Biologics Inc?
How many employess does Theriva Biologics Inc has?

Latest TOVX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.